104 related articles for article (PubMed ID: 38733211)
1. Time to full weight-bearing with the use of a calcium sulfate-calcium phosphate bone substitute as a bone void filler following extended curettage in the treatment of primary benign bone tumours.
Gyemi L; Selznick A; Petrisor B; Ghert M
J Orthop Surg (Hong Kong); 2024; 32(2):10225536241254200. PubMed ID: 38733211
[TBL] [Abstract][Full Text] [Related]
2. Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors.
Evaniew N; Tan V; Parasu N; Jurriaans E; Finlay K; Deheshi B; Ghert M
Orthopedics; 2013 Feb; 36(2):e216-22. PubMed ID: 23380017
[TBL] [Abstract][Full Text] [Related]
3. Long-term Follow-up of the Use of a Synthetic Bone Graft Composite in the Surgical Management of Primary Bone Tumors.
Multani I; Schneider P; Baldawi H; Deheshi B; Ghert M
Orthopedics; 2018 Nov; 41(6):e868-e875. PubMed ID: 30371921
[TBL] [Abstract][Full Text] [Related]
4. Chronology of the Radiographic Appearances of the Calcium Sulfate-Calcium Phosphate Synthetic Bone Graft Composite Following Resection of Bone Tumors: A Follow-up Study of Postoperative Appearances.
Tan V; Evaniew N; Finlay K; Jurriaans E; Ghert M; Deheshi B; Parasu N
Can Assoc Radiol J; 2016 Feb; 67(1):21-7. PubMed ID: 25599610
[TBL] [Abstract][Full Text] [Related]
5. Filling of the resultant cavity after curettage of benign bone tumours is still controversial.
Ismail TB; Mahmoud MM; Ahmed OE; Bola AH; Bahaa ZH
Med J Malaysia; 2023 Mar; 78(2):163-170. PubMed ID: 36988525
[TBL] [Abstract][Full Text] [Related]
6. Aqueous calcium sulphate as bone graft for voids following open curettage of bone tumours.
Johnson LJ; Clayer M
ANZ J Surg; 2013 Jul; 83(7-8):564-70. PubMed ID: 22925525
[TBL] [Abstract][Full Text] [Related]
7. Bone defects following curettage do not necessarily need augmentation.
Hirn M; de Silva U; Sidharthan S; Grimer RJ; Abudu A; Tillman RM; Carter SR
Acta Orthop; 2009 Feb; 80(1):4-8. PubMed ID: 19234881
[TBL] [Abstract][Full Text] [Related]
8. Treatment alternatives and clinical outcomes of bone filling after benign tumour curettage. A systematic review.
Gava NF; Engel EE
Orthop Traumatol Surg Res; 2022 Jun; 108(4):102966. PubMed ID: 34033919
[TBL] [Abstract][Full Text] [Related]
9. Increased bone formation using calcium sulfate-calcium phosphate composite graft.
Urban RM; Turner TM; Hall DJ; Inoue N; Gitelis S
Clin Orthop Relat Res; 2007 Jun; 459():110-7. PubMed ID: 17415007
[TBL] [Abstract][Full Text] [Related]
10. Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius.
Abuhejleh H; Wunder JS; Ferguson PC; Isler MH; Mottard S; Werier JA; Griffin AM; Turcotte RE
Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):11-17. PubMed ID: 31297594
[TBL] [Abstract][Full Text] [Related]
11. Healing bone lesion defects using injectable CaSO
Hall DJ; Turner TM; Urban RM
J Biomed Mater Res B Appl Biomater; 2019 Feb; 107(2):408-414. PubMed ID: 29663638
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of ultraporous β-tricalcium phosphate (vitoss) as bone graft substitute for cavitary defects in benign and low-grade malignant bone tumors.
Van Hoff C; Samora JB; Griesser MJ; Crist MK; Scharschmidt TJ; Mayerson JL
Am J Orthop (Belle Mead NJ); 2012 Jan; 41(1):20-3. PubMed ID: 22389890
[TBL] [Abstract][Full Text] [Related]
13. Intraosseous lipoma: a report of two cases with use of tricalcium phosphate bone void filler.
Japour C; Giorgini R; Aska G; Thomas M; Reynolds E
J Am Podiatr Med Assoc; 2010; 100(6):487-92. PubMed ID: 21084535
[TBL] [Abstract][Full Text] [Related]
14. Unexpected radiographic lucency following grafting of bone defects with calcium sulfate/tricalcium phosphate bone substitute.
Auston DA; Feibert M; Craig T; Damron TA
Skeletal Radiol; 2015 Oct; 44(10):1453-9. PubMed ID: 26081807
[TBL] [Abstract][Full Text] [Related]
15. Treatment of unicameral bone cysts in pediatric patients with an injectable regenerative graft: a preliminary report.
Gentile JV; Weinert CR; Schlechter JA
J Pediatr Orthop; 2013; 33(3):254-61. PubMed ID: 23482260
[TBL] [Abstract][Full Text] [Related]
16. Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®.
Friesenbichler J; Maurer-Ertl W; Sadoghi P; Pirker-Fruehauf U; Bodo K; Leithner A
Clin Orthop Relat Res; 2014 Mar; 472(3):976-82. PubMed ID: 24078171
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of proximal femoral benign lesions by proximal femoral nail anti-rotation combined with curettage and bone graft through the Watson-Jones approach].
Liu H; Xiong Y; Fang X; Duan H
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 Jul; 32(7):893-898. PubMed ID: 30129314
[TBL] [Abstract][Full Text] [Related]
18. Function after injection of benign bone lesions with a bioceramic.
Fillingham YA; Lenart BA; Gitelis S
Clin Orthop Relat Res; 2012 Jul; 470(7):2014-20. PubMed ID: 22290129
[TBL] [Abstract][Full Text] [Related]
19. Early postoperative compilations of bone filling in curettage defects.
Chen CJ; Brien EW
J Orthop Surg Res; 2019 Aug; 14(1):261. PubMed ID: 31419993
[TBL] [Abstract][Full Text] [Related]
20. Long bones giant cells tumors: treatment by curretage and cavity filling cementation.
Fraquet N; Faizon G; Rosset P; Phillipeau J-; Waast D; Gouin F
Orthop Traumatol Surg Res; 2009 Oct; 95(6):402-6. PubMed ID: 19767256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
